{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["398(12)"],"submitter":["Balbaa E"],"pubmed_abstract":["Vascular complications after percutaneous cardiac interventions are a significant cause of morbidity that affects post-procedural prognosis. Data about the efficacy and safety of routine protamine sulphate to prevent these complications remain scarce. Hence, we aim to assess the efficacy and safety of routine protamine sulphate use for heparin reversal in patients undergoing percutaneous cardiac interventions. We systematically searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) until September 2024. The RCTs' quality was assessed using the Cochrane tool (RoB 2). Using R, we pooled dichotomous outcomes using risk ratios (RR) and continuous outcomes using mean differences (MD), both along the corresponding 95% Confidence interval (CI). PROSP"],"journal":["Naunyn-Schmiedeberg's archives of pharmacology"],"pagination":["16507-16520"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12678601"],"repository":["biostudies-literature"],"pubmed_title":["Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials."],"pmcid":["PMC12678601"],"pubmed_authors":["Fatiem AR","Naeem A","Abuelazm M","Elbataa A","Bazzazeh M","Balbaa E","Tawfik AM","Altobaishat O","Gadelmawla AF","Ali K"],"additional_accession":[]},"is_claimable":false,"name":"Protamine sulphate for heparin reversal in percutaneous cardiac interventions: a systematic review and meta-analysis of randomized controlled trials.","description":"Vascular complications after percutaneous cardiac interventions are a significant cause of morbidity that affects post-procedural prognosis. Data about the efficacy and safety of routine protamine sulphate to prevent these complications remain scarce. Hence, we aim to assess the efficacy and safety of routine protamine sulphate use for heparin reversal in patients undergoing percutaneous cardiac interventions. We systematically searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) until September 2024. The RCTs' quality was assessed using the Cochrane tool (RoB 2). Using R, we pooled dichotomous outcomes using risk ratios (RR) and continuous outcomes using mean differences (MD), both along the corresponding 95% Confidence interval (CI). PROSP","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T22:36:56.772Z","creation":"2026-05-23T03:10:30.311Z"},"accession":"S-EPMC12678601","cross_references":{"pubmed":["40613937"],"doi":["10.1007/s00210-025-04369-4"]}}